CagriSema is an investigational once-weekly injection from Novo Nordisk that combines two drugs in a single shot: semaglutide (the GLP-1 medication in Wegovy and Ozempic) and cagrilintide (a long-acting amylin analog that is itself still experimental). It is not FDA approved and is not available by prescription, from TrimRx or anywhere else, as of mid-2026. In its largest trial it produced about 22.7% average weight loss. Novo Nordisk filed for FDA approval in December 2025, with a decision expected in late 2026. Here is what it is, how it works, and where it fits.<\/p>\n
CagriSema pairs two molecules that curb appetite through different pathways. Semaglutide is a GLP-1 receptor agonist that reduces hunger and slows how fast the stomach empties, the same active ingredient in Wegovy and Ozempic. Cagrilintide is an amylin analog, and amylin is a hormone that signals fullness through the brainstem, working alongside GLP-1 rather than duplicating it.<\/p>\n
Combining them is the whole idea: two satiety signals instead of one. If it reaches the market, CagriSema would be the first fixed-dose amylin-plus-GLP-1 combination for weight management. The studied dose is 2.4 mg of each component, given as one weekly subcutaneous injection.<\/p>\n
| Trial<\/th>\n | Population<\/th>\n | Average weight loss<\/th>\n | In-trial comparison<\/th>\n<\/tr>\n<\/thead>\n |
|---|---|---|---|
| REDEFINE 1<\/td>\n | Obesity, no diabetes<\/td>\n | ~22.7% (adherent)<\/td>\n | Semaglutide alone ~16%; placebo ~3%<\/td>\n<\/tr>\n |
| REDEFINE 2<\/td>\n | Obesity + type 2 diabetes<\/td>\n | ~15.7%<\/td>\n | Placebo ~3%<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n In REDEFINE 1, the main obesity trial of 3,417 adults, CagriSema produced about 22.7% average weight loss over 68 weeks in people who stayed on treatment, compared with roughly 16% for semaglutide alone in the same study. That puts CagriSema in the same range as tirzepatide (Zepbound) and clearly ahead of semaglutide on its own.<\/p>\n One nuance worth knowing: that 22.7% came in below what Novo Nordisk had projected (around 25%), which disappointed investors when the data first read out. The drug works well; it simply did not clear the very high bar some had set.<\/p>\n In REDEFINE 2, which enrolled people with type 2 diabetes, average weight loss was about 15.7%, lower because weight reduction tends to run smaller in people with diabetes, a pattern seen across this drug class.<\/p>\n Side effects<\/h3>\nBecause semaglutide is one of its components, CagriSema’s side effects look like the GLP-1 class you may already know. In trials the most common were gastrointestinal: nausea (around 55% of participants), constipation, and vomiting, mostly mild to moderate and concentrated during the dose-increase period. Discontinuation due to side effects was low, at roughly 6%.<\/p>\n When could it be available?<\/h3>\nNovo Nordisk submitted CagriSema to the FDA in December 2025, based on the REDEFINE 1 and REDEFINE 2 results. The company has said it expects an FDA decision by late 2026. If approved, a commercial launch would likely follow in late 2026 or early 2027. Until then, the only way to access CagriSema is through a clinical trial. It cannot be prescribed or compounded, and any product sold online as “CagriSema” is not the real, regulated medication.<\/p>\n How CagriSema compares to what’s available now<\/h3>\nCagriSema is not the only high-efficacy option, and the approved drugs are available today. Tirzepatide (Zepbound) has produced around 20% average weight loss<\/a> in its trials, and semaglutide (Wegovy) delivers roughly 15%<\/a> with the added benefit of a proven cardiovascular indication. Both can be prescribed now, and both have far longer real-world track records than CagriSema, which has not yet been used outside of trials.<\/p>\n Consider a scenario where someone is researching their options and wants the most effective drug possible. The reasonable approach is usually not to wait one to two years for a drug that may or may not be approved on schedule. It is to start an approved, available medication now and reassess if CagriSema launches and turns out to fit better. Weight that comes off sooner is weight you are not carrying while you wait, and decisions like how long to stay on a GLP-1<\/a> are easier to make with a drug you can actually start.<\/p>\n |